ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of docetaxel when given with
zoledronic acid in patients with bone metastasis from prostate cancer that has not responded
to hormone therapy.